帕金森病(Parkinson’sdisease,PD)是一种独特的临床综合征,有多种病因和临床表现。除了传染性原因,PD是一种快速发展的神经系统疾病,频率在全球范围内上升。值得注意的是,对分子途径的认识提高和新的诊断方法的发展可能导致对PD患者更好的治疗。在这方面,对ceRNA轴的研究数量正在增加,强调这些轴在PD中的重要性。CeRNA是通过竞争共享的microRNA(miRNA)彼此交叉调节的转录物。这些转录物可以是编码RNA(mRNA)或非编码RNA(ncRNA)。这项研究使用系统评价来评估PD中CERNA的验证环。Prisma指南用于进行系统评价,这需要系统地检查七个数据库的文章。在309个条目中,40篇文章符合所有纳入标准,并在适当的表格中进行了总结。CeRNA轴已经通过轴的共享重要组成部分之一进行了描述,包括lncRNAs,如NEAT1,SNHG家族,HOTAIR,MALAT1,XIST,circRNAs,和lincRNAs。了解这种调节结构的多个方面可能有助于阐明PD的未知原因,并提供创新的分子治疗靶标和医学领域。
Parkinson\'s disease (PD) is a distinctive clinical syndrome with several causes and clinical manifestations. Aside from an infectious cause, PD is a rapidly developing neurological disorder with a global rise in frequency. Notably, improved knowledge of molecular pathways and the developing novel diagnostic methods may result in better therapy for PD patients. In this regard, the amount of research on
ceRNA axes is rising, highlighting the importance of these axes in PD. CeRNAs are transcripts that cross-regulate one another via competition for shared microRNAs (miRNAs). These transcripts may be either coding RNAs (mRNAs) or non-coding RNAs (ncRNAs). This research used a systematic
review to assess validated loops of
ceRNA in PD. The Prisma guideline was used to conduct this systematic
review, which entailed systematically examining the articles of seven databases. Out of 309 entries, forty articles met all criteria for inclusion and were summarized in the appropriate table.
CeRNA axes have been described through one of the shared vital components of the axes, including lncRNAs such as NEAT1, SNHG family, HOTAIR, MALAT1, XIST, circRNAs, and lincRNAs. Understanding the multiple aspects of this regulatory structure may aid in elucidating the unknown causal causes of PD and providing innovative molecular therapeutic targets and medical fields.